Shield Therapeutics PLC (STX)
Industry Drug Manufacturers - Specialty & Generic
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
9.00p
Buy
9.30p
0.05p (+0.54%)
Prices updated at 23 Apr 2026, 15:18 BST
| Prices minimum 15 mins delay
Prices in GBX
Shield Therapeutics PLC is focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. It is a specialty pharmaceutical company.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Chairman
Mr. Hans Peter Hasler
CEO
Mr. Karl Anders Lundstrom
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
63
Head office
Northern Design Centre
Newcastle
United Kingdom
NE8 3DF
Key personnel
Owner name | Salary |
|---|---|
Mr. Peter Hermann William Llewellyn-Davies Non-Executive Director, Vice Chairman | - |
Mr. Hans Peter Hasler Non-Executive Director, Chairman | - |
Ms. Maria Fabiana Lacerca-Allen Non-Executive Director | - |
Dr. Christian Schweiger Non-Executive Director | - |
Mr. Karl Anders Lundstrom Executive Director, Chief Executive Officer | - |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| Miton Asset Management Limited | 5,725,916 |
| Premier Miton UK Smaller Companies | 5,725,916 |
| Mandarine Gestion | 5,030,000 |
| Mandarine Europe Microcap | 4,500,000 |
| IFSL Marlborough Nano Cap Growth Fund | 1,250,000 |
Director dealings
Date | Action |
|---|---|
| No data | |
Please note that past performance is not a reliable indicator of future returns.